Is Kiora Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: KPRX) stock is to Buy KPRX stock.
Out of 1 analyst, 0 (0%) are recommending KPRX as a Strong Buy, 1 (100%) are recommending KPRX as a Buy, 0 (0%) are recommending KPRX as a Hold, 0 (0%) are recommending KPRX as a Sell, and 0 (0%) are recommending KPRX as a Strong Sell.
What is KPRX's earnings growth forecast for 2025-2025?
(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.
Kiora Pharmaceuticals's earnings in 2025 is $3,594,733.
In 2025, KPRX is forecast to generate -$8,972,356 in earnings, with the lowest earnings forecast at -$8,972,356 and the highest earnings forecast at -$8,972,356.
What is KPRX's forecast return on equity (ROE) for 2025-2027?
(NASDAQ: KPRX) forecast ROE is N/A, which is considered weak.
What is KPRX's Price Target?
According to 1 Wall Street analyst that have issued a 1 year KPRX price target, the average KPRX price target is $10.00, with the highest KPRX stock price forecast at $10.00 and the lowest KPRX stock price forecast at $10.00.
The Wall Street analyst predicted that Kiora Pharmaceuticals's share price could reach $10.00 by Mar 28, 2026. The average Kiora Pharmaceuticals stock price prediction forecasts a potential upside of 248.43% from the current KPRX share price of $2.87.
What is KPRX's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: KPRX) Kiora Pharmaceuticals's current Earnings Per Share (EPS) is $0.93. In 2025, KPRX's EPS is forecast to hit -$2.99 (min: -$2.99, max: -$2.99).
What is KPRX's forecast return on assets (ROA) for 2025-2027?
(NASDAQ: KPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 22.35%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.